114 related articles for article (PubMed ID: 27922689)
1. Rb knockdown accelerates bladder cancer progression through E2F3 activation.
Wang JP; Jiao Y; Wang CY; Xu ZB; Zhang B
Int J Oncol; 2017 Jan; 50(1):149-160. PubMed ID: 27922689
[TBL] [Abstract][Full Text] [Related]
2. Rb deficiency accelerates progression of carcinoma of the urinary bladder in vivo and in vitro through inhibiting autophagy and apoptosis.
Wang CY; Xu ZB; Wang JP; Jiao Y; Zhang B
Int J Oncol; 2017 Apr; 50(4):1221-1232. PubMed ID: 28259945
[TBL] [Abstract][Full Text] [Related]
3. [miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway].
Li X; Han X; Yang J; Sun J; Wei P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Oct; 33(10):1360-1364. PubMed ID: 29169421
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
5. QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling.
Shi F; Deng Z; Zhou Z; Jiang CY; Zhao RZ; Sun F; Cui D; Bei XY; Yang BY; Sun Q; Wang XJ; Wu Q; Xia SJ; Han BM
J Cell Mol Med; 2019 Oct; 23(10):6578-6594. PubMed ID: 31449345
[TBL] [Abstract][Full Text] [Related]
6. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
Olsson AY; Feber A; Edwards S; Te Poele R; Giddings I; Merson S; Cooper CS
Oncogene; 2007 Feb; 26(7):1028-37. PubMed ID: 16909110
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3.
Huang L; Luo J; Cai Q; Pan Q; Zeng H; Guo Z; Dong W; Huang J; Lin T
Int J Cancer; 2011 Apr; 128(8):1758-69. PubMed ID: 20549700
[TBL] [Abstract][Full Text] [Related]
8. High expression of TMEM40 is associated with the malignant behavior and tumorigenesis in bladder cancer.
Zhang ZF; Zhang HR; Zhang QY; Lai SY; Feng YZ; Zhou Y; Zheng SR; Shi R; Zhou JY
J Transl Med; 2018 Jan; 16(1):9. PubMed ID: 29351801
[TBL] [Abstract][Full Text] [Related]
9. Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles.
Liu H; Tang X; Srivastava A; Pécot T; Daniel P; Hemmelgarn B; Reyes S; Fackler N; Bajwa A; Kladney R; Koivisto C; Chen Z; Wang Q; Huang K; Machiraju R; Sáenz-Robles MT; Cantalupo P; Pipas JM; Leone G
Nat Cell Biol; 2015 Aug; 17(8):1036-48. PubMed ID: 26192440
[TBL] [Abstract][Full Text] [Related]
10. Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis.
Shinohara H; Zhou J; Yoshikawa K; Yazumi S; Ko K; Yamaoka Y; Mizukami T; Yoshida T; Akinaga S; Tamaoki T; Motoda H; Benedict WF; Takahashi R
Br J Cancer; 2000 Oct; 83(8):1039-46. PubMed ID: 10993652
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome regulation and chromatin occupancy by E2F3 and MYC in mice.
Tang X; Liu H; Srivastava A; Pécot T; Chen Z; Wang Q; Huang K; Sáenz-Robles MT; Cantalupo P; Pipas J; Leone G
Sci Data; 2016 Feb; 3():160008. PubMed ID: 26881867
[TBL] [Abstract][Full Text] [Related]
12. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
13. Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues.
Parisi T; Yuan TL; Faust AM; Caron AM; Bronson R; Lees JA
Mol Cell Biol; 2007 Mar; 27(6):2283-93. PubMed ID: 17210634
[TBL] [Abstract][Full Text] [Related]
14. Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context.
Dean JL; McClendon AK; Stengel KR; Knudsen ES
Oncogene; 2010 Jan; 29(1):68-80. PubMed ID: 19802012
[TBL] [Abstract][Full Text] [Related]
15. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.
He X; Chai P; Li F; Zhang L; Zhou C; Yuan X; Li Y; Yang J; Luo Y; Ge S; Zhang H; Jia R; Fan X
Mol Cancer; 2020 Jul; 19(1):115. PubMed ID: 32669100
[TBL] [Abstract][Full Text] [Related]
16. microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer.
Lei M; Xie W; Sun E; Sun Y; Tian D; Liu C; Han R; Li N; Liu M; Han R; Liu L
DNA Cell Biol; 2015 Oct; 34(10):626-32. PubMed ID: 26230405
[TBL] [Abstract][Full Text] [Related]
17. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
Akeno N; Miller AL; Ma X; Wikenheiser-Brokamp KA
Oncogene; 2015 Jan; 34(5):589-99. PubMed ID: 24469052
[TBL] [Abstract][Full Text] [Related]
18. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.
Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R
Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223
[TBL] [Abstract][Full Text] [Related]
19. An Rb family-independent E2F3 transcription factor variant impairs STAT5 signaling and mammary gland remodeling during pregnancy in mice.
Liao Y; Du W
J Biol Chem; 2018 Mar; 293(9):3156-3167. PubMed ID: 29330306
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells.
Terada N; Lucas JJ; Gelfand EW
J Immunol; 1991 Jul; 147(2):698-704. PubMed ID: 1906503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
